Skip to main content

Table 1 Baseline Characteristics of Healthy Living After Cancer (HLaC) participants overall and by Cancer Council

From: Translating research into practice: outcomes from the Healthy Living after Cancer partnership project

Overall

Overall

A

B

C

D

p a

n

Summary

n

Summary

n

Summary

n

Summary

n

Summary

Age (M ± SD)

786

57.52 ± 11.44

248

57.43 ± 11.74

170

58.26 ± 10.52

200

55.34 ± 11.63

168

59.52 ± 11.29

0.004

 Male

94

12.0%

32

12.9%

16

9.4%

29

14.5%

17

10.1%

0.384

 Female

692

88.0%

216

87.1%

154

90.6%

171

85.5%

151

89.9%

 

Ethnicity

          

0.006 b

 Aboriginal or Torres Strait Islander

7

0.9%

5

2.0%

1

0.6%

1

0.5%

0

0.0%

 

 Asian

39

5.0%

14

5.6%

3

1.8%

13

6.5%

9

5.4%

 

 Caucasian or white

705

89.7%

212

85.5%

162

95.3%

179

89.50%

152

90.5%

 

 Middle Eastern

9

1.1%

3

1.2%

2

1.2%

3

1.5%

1

0.6%

 

 Pacific Islander

7

0.9%

5

2.0%

0

0.0%

0

0.0%

2

1.2%

 

 South American

7

0.9%

5

2.0%

0

0.0%

1

0.5%

1

0.6%

 

 Other

10

1.3%

3

1.2%

1

0.6%

3

1.5%

3

1.8%

 

 Not reported

2

0.3%

1

0.4%

1

0.6%

0

0.0%

0

0.0%

 

Comorbidities

 0

160

20.4%

61

24.6%

29

17.1%

44

22.0%

26

15.5%

0.005

 1

189

24.0%

68

27.4%

38

22.4%

48

24.0%

35

20.8%

 

 2

160

20.4%

46

18.5%

41

24.1%

40

20.0%

33

19.6%

 

 3

123

15.6%

28

11.3%

30

17.6%

34

17.0%

31

18.5%

 

  ≥ 4

154

19.6%

45

18.1%

32

18.8%

34

17.0%

43

25.6%

 

Education

  < High School

115

14.6%

34

13.7%

33

19.4%

31

15.4%

17

10.1%

0.004

 High School

71

9.0%

16

6.5%

24

14.1%

19

9.5%

12

7.1%

 

 TAFE / Technical

267

34.0%

72

29.0%

57

33.5%

69

34.5%

69

41.1%

 

 University

333

42.4%

126

50.8%

56

32.9%

81

40.5%

70

41.7%

 

BMI, kg/m2 M ± SD

786

28.81 ± 6.51

248

27.67 ± 6.47

170

30.14 ± 6.52

200

29.05 ± 6.28

168

28.85 ± 6.59

0.002

Employment

 Full time

149

19.0%

48

19.4%

25

14.7%

44

22.0%

32

19.0%

0.261

 Part-time / Casual

231

29.4%

69

27.8%

50

29.4%

61

30.5%

51

30.4%

 

 Self employed

13

1.7%

4

1.6%

1

0.6%

5

2.5%

3

1.8%

 

 Home duties

62

7.9%

21

8.5%

14

8.2%

15

7.5%

12

7.1%

 

 Retired

164

20.9%

57

23.0%

29

17.1%

34

17.0%

44

26.2%

 

 Unable to work

104

13.2%

32

12.9%

34

20.0%

24

12.0%

14

8.3%

 

 Other not working

63

8.0%

17

6.9%

17

10.0%

17

8.5%

12

7.1%

 

Alcohol (standard drinks/ week) c

 0

390

49.6%

120

48.4%

81

47.6%

101

50.5%

88

52.4%

0.867

  > 0 to < 21

370

47.1%

118

47.6%

82

48.2%

96

48.0%

74

44.0%

 

 21 to < 35

21

2.7%

8

3.2%

6

3.5%

2

1.0%

5

3.0%

 

  ≥ 35

5

0.6%

2

0.8%

1

0.6%

1

0.5%

1

0.6%

 

Marital status

 Married / living together

501

63.7%

160

64.5%

109

64.1%

120

60.0%

112

66.7%

0.681

 Divorced

124

15.8%

34

13.7%

30

17.6%

32

16.0%

28

16.7%

 

 Separated

31

3.9%

14

5.6%

4

2.4%

7

3.5%

6

3.6%

 

 Widowed

34

4.3%

13

5.2%

6

3.5%

10

5.0%

5

3.0%

 

 Never married

96

12.2%

27

10.9%

21

12.4%

31

15.5%

17

10.1%

 

IRSAD

 Bottom 30% of state

133

17.1%

35

14.1%

35

21.2%

40

20.0%

23

13.9%

0.268

 Middle 40% of state

299

38.5%

93

38.0%

66

40.0%

77

38.5%

63

51.8%

 

 Top 30% of state

344

44.3%

117

47.8%

64

38.8%

83

41.5%

80

48.2%

 

 Missing

10

3

5

0

2

 

Geographic location

 Major City

594

76.3%

198

80.8%

112

67.1%

149

74.5%

135

80.4%

0.005

 Elsewhere

184

23.7%

47

19.2%

55

32.9%

51

25.5%

31

18.7%

 

 Missing

8

3

3

0

2

 

Years since diagnosis: M ± SD, Median (min, max)

786

1.91 ± 3.02

248

2.11 ± 2.72

170

1.86 ± 2.98

200

1.70 ± 1.95

168

1.92 ± 4.28

0.316

1 (0, 54)

 

1 (0, 20)

 

1 (0, 32)

 

1 (0, 15)

 

1 (0, 54)

 

Cancer type

 Breast

484

61.6%

143

57.7%

113

66.5%

114

56.7%

114

67.9%

0.113 b

 Cervical

12

1.5%

6

2.4%

1

0.6%

4

2.0%

1

0.6%

 

 Colorectal / bowel

71

9.0%

18

7.3%

16

9.4%

22

11.0%

15

8.9%

 

 Kidney

7

0.9%

2

0.8%

1

0.6%

4

2.0%

0

0.0%

 

 Lung

7

0.9%

3

1.2%

0

0.0%

1

0.5%

3

1.8%

 

 Lymphoma

66

8.4%

22

8.9%

15

8.8%

17

8.5%

12

7.1%

 

 Melanoma

2

0.3%

0

0.0%

0

0.0%

1

0.5%

1

0.6%

 

 Prostate

30

3.8%

11

4.4%

7

4.1%

5

2.5%

7

4.2%

 

 Stomach

2

0.3%

0

0.0%

0

0.0%

2

1.0%

0

0.0%

 

 Testicular

3

0.4%

0

0.0%

1

0.6%

2

1.0%

0

0.0%

 

 Ovarian

19

2.4%

10

4.0%

4

2.4%

4

2.0%

1

0.6%

 

 Uterine

15

1.9%

2

0.8%

2

1.2%

9

4.5%

2

1.2%

 

 Endometrial

10

1.3%

5

2.0%

2

1.2%

2

1.0%

1

0.6%

 

 Leukaemia

11

1.4%

5

2.0%

4

2.4%

2

1.0%

0

0.0%

 

 Other

47

6.0%

21

8.5%

4

2.4%

11

5.5%

11

6.5%

 

Treatment

 Surgery

686

87.3%

208

83.9%

147

86.5%

178

89.0%

153

91.1%

0.140

 Chemotherapy

531

67.6%

166

66.9%

123

72.4%

128

64.0%

114

67.9%

0.389

 Radiotherapy

469

59.7%

155

62.5%

103

60.6%

119

59.5%

92

54.8%

0.465

 Hormone therapy

343

43.6%

105

42.3%

62

36.5%

92

46.0%

84

50.0%

0.073

 trastuzumab

75

9.5%

19

7.7%

22

12.9%

13

6.5%

21

12.5%

0.069

  1. IRSAD index of relative socioeconomic advantage and disadvantage, BMI body mass index
  2. a p for difference between cancer council by ANOVA (M ± SD) or chi-square test (%)
  3. b due to insufficient frequencies chi-square test based on collapsed categories: Caucasian / other; breast / colorectal or bowel / lymphoma / prostate / other
  4. c Measured per week: cut-offs based on daily thresholds of none, > 0 to < 3/day, 3 to < 5 / day, and > =5 /day)